Helsinki, Finland, 26 June 2025: Nordhealth AS (the "Company") hereby launches an offer to purchase up to 300,000 of its own shares (the "Offering"). The Offering will be carried out as a reversed book-building process where the Company, through DNB Carnegie, will receive offers for desired volume(s) for sale from the shareholders.    

All shareholders in the Company are invited to sell shares in the Offering, subject to the restrictions set out herein.

The Company has mandated DNB Carnegie as bookrunner for the Offering and shareholders with interest to sell shares may contact DNB Carnegie via email demand@dnb.no or by phone +47 24 16 90 20 before the end of the Application Period (as defined below). Existing shareholders in the Company who would like to participate in the Offering who are not registered as clients of the DNB Carnegie must establish a client relationship before participating.

The Offering starts on 26 June 2025 at 09:00 CEST and will close no later than 2 July 2025 at 16:30 CEST (the "Application Period"). The final price offered by the Company and the allocation of tendered shares are expected to be resolved by the Company on or about 3 July 2025, the trade date is expected to be on or about 3 July 2025, and the settlement date is expected to be on or about 7 July 2025. The settlement will be conducted on a normal delivery-versus-payment basis. The Company reserves the right to extend the Application Period at its own discretion. If the Application Period is extended, the other dates referred to herein may be amended accordingly.

The shares will be purchased at a maximum of NOK 37 per share, which is above the 60 days average volume weighted average price (VWAP) of the Company's shares. The final purchase price will be identical for all selling shareholders.

The Company will in the event of receiving offers exceeding a total of 300,000 shares, allocate shares at its discretion in accordance with the best interest of the Company, taking into account the prices and volumes offered, with equal treatment of the shareholders as the primary objective.

The Company reserves the right to, at its own discretion, buy back fewer shares or no shares at all, to terminate the Offering or make any amendments regarding the volume or other terms of the Offering at any time until the time of completion of the Offering.

Any shares acquired as part of the Offering will be used as consideration in future acquisitions by the Company, as part of the employee share program, or absent of this, be cancelled. Any shares purchased will be held in treasury until used for any of the above purposes.

The Offering is launched, and repurchases are made, in accordance with the authorisation granted to the board of directors by the Company's general meeting held on 27 May 2025

For further information, please contact:

DNB Carnegie, demand@dnb.no, +47 24 16 90 20

Charles MacBain, CEO, charles.macbain@nordhealth.com, +44 75 3903 2200

Alexander Cram, CFO, alexander.cram@nordhealth.com, +32 470 69 30 20